GenSight Biologics raises EUR 1 million in private placement backed by Heights Capital, Invus
Bitget2026/10/08 05:01GenSight Biologics priced a € 1 million private placement backed by existing shareholders Heights Capital and Invus. Structure combines 2,597,404 new shares, 11,940,300 pre-funded warrants, and 14,537,704 investor warrants. Gross proceeds € 1 million; net proceeds about € 950,000. Funds earmarked for operations and working capital pending structural financing for the Phase III RECOVER trial. New shares priced at € 0.077 per ABSA; pre-funded unit priced at € 0.067; investor warrant exercise price € 0.0497. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gensight Biologics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007598026) on October 08, 2026, and is solely responsible for the information contained therein.
- GenSight Biologics priced a € 1 million private placement backed by existing shareholders Heights Capital and Invus.
- Structure combines 2,597,404 new shares, 11,940,300 pre-funded warrants, and 14,537,704 investor warrants.
- Gross proceeds € 1 million; net proceeds about € 950,000.
- Funds earmarked for operations and working capital pending structural financing for the Phase III RECOVER trial.
- New shares priced at € 0.077 per ABSA; pre-funded unit priced at € 0.067; investor warrant exercise price € 0.0497.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Crypto prices
More
